risedronic acid has been researched along with Adverse Drug Event in 7 studies
Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Bone mineral density, bone turnover markers, fractures, and adverse events were evaluated." | 2.73 | Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. ( Beary, JF; Benhamou, CL; Boonen, S; Burgio, DE; Delmas, PD; Eusebio, RA; Man, Z; Matzkin, E; McClung, MR; Racewicz, A; Roux, C; Zanchetta, JR, 2008) |
| " The mechanism, efficacy, dosing options, and tolerability of risedronate are reviewed." | 2.45 | Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. ( Rackoff, P, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, Z | 1 |
| Shi, Q | 1 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Fang, H | 1 |
| Tong, W | 1 |
| Sakatis, MZ | 1 |
| Reese, MJ | 1 |
| Harrell, AW | 1 |
| Taylor, MA | 1 |
| Baines, IA | 1 |
| Chen, L | 1 |
| Bloomer, JC | 1 |
| Yang, EY | 1 |
| Ellens, HM | 1 |
| Ambroso, JL | 1 |
| Lovatt, CA | 1 |
| Ayrton, AD | 1 |
| Clarke, SE | 1 |
| Grosso, A | 1 |
| Douglas, I | 1 |
| Hingorani, A | 1 |
| MacAllister, R | 1 |
| Smeeth, L | 1 |
| Rackoff, P | 1 |
| Landfeldt, E | 1 |
| Lang, A | 1 |
| Robbins, S | 1 |
| Ström, O | 1 |
| Delmas, PD | 1 |
| McClung, MR | 1 |
| Zanchetta, JR | 1 |
| Racewicz, A | 1 |
| Roux, C | 1 |
| Benhamou, CL | 1 |
| Man, Z | 1 |
| Eusebio, RA | 1 |
| Beary, JF | 1 |
| Burgio, DE | 1 |
| Matzkin, E | 1 |
| Boonen, S | 1 |
| Hussar, DA | 1 |
1 review available for risedronic acid and Adverse Drug Event
| Article | Year |
|---|---|
Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis.
Topics: Aged; Bone Density Conservation Agents; Dose-Response Relationship, Drug; Drug-Related Side Effects | 2009 |
1 trial available for risedronic acid and Adverse Drug Event
| Article | Year |
|---|---|
Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis.
Topics: Bone Density; Drug-Related Side Effects and Adverse Reactions; Etidronic Acid; Female; Humans; Middl | 2008 |
5 other studies available for risedronic acid and Adverse Drug Event
| Article | Year |
|---|---|
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme | 2012 |
Oral bisphosphonates and risk of atrial fibrillation and flutter in women: a self-controlled case-series safety analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Atrial Fibrillation; Atrial Flutter; Bone Density Conservation | 2009 |
Gastrointestinal tolerability and patterns of switching in patients treated for primary osteoporosis: the Swedish Adherence Register Analysis (SARA).
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Drug Substitution; Drug-Rela | 2011 |
New drugs 99, Part III.
Topics: Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Antibodies, Monoclonal; Antibodies, Monoclona | 1999 |